THE SOLUTION
A New Standard in Regenerative Medicine
Consistent, potent, and scalable neonatal cell sources designed for real-world therapeutic impact.
~0% Variability
Manufacturing Consistency
Adult stem cells vary significantly between donors, making FDA-level consistency difficult. Our lead program, STM-01, and its secretome, STM-2, are derived from neonatal sources, enabling near-zero variability and reliable, scalable cell-based therapies.
10× More yield
Scale & Cost of Goods
Exponentially more nCPCs can be produced from a single donor compared to adult cells, driving down production costs and minimizing the number of donors needed.
↑3× Potency
Maximal Potency
Stem cell regenerative potential declines with donor age. Derived from young neonatal sources, our lead nCPC, STM-01, has demonstrated significantly higher potency than adult-derived stem cells in peer-reviewed studies.
100% Ethical
Non-Fetal Source
While embryonic or fetal stem cells also possess minimal inter-donor variability, their use is complicated by ethical and political considerations. Cells sourced from neonates avoid these issues while maintaining their potency and manufacturing advantages.
Learn More About Our Ongoing Clinical Studies
VIEW CLINICAL TRIALS
EMAIL ALERTS
Be in the know.
Subscribe to email updates for the latest news, clinical progress, and company milestones.
Secretome Therapeutics is committed to developing promising new therapies to address the unmet medical needs of patients suffering from rare and serious diseases with unmet need.
We currently have an early-stage investigational medicine in our product pipeline for the treatment of heart failure with preserved ejection fraction, and for dilated cardiomyopathy. Our goal is to provide access to our medicine at the appropriate time and in a manner that is most beneficial to the relevant patient populations. We believe enrollment in our ongoing clinical trials is the safest and most effective way of achieving this goal.
We do recognize that some patients will not be eligible for our clinical trials and may wish to access our products through expanded access. However, at this time, we do not have the resources available to offer expanded access use of our investigational medicine.
We encourage all patients and physicians who are interested in accessing our investigational medicine to visit clinicaltrials.gov to find out about enrolling.
Secretome Therapeutics may revise this expanded access policy at any time. Additionally, the posting of this policy by Secretome Therapeutics does not serve as a guarantee of access to any specific investigational new drug by any individual patient.
If you have any questions, please reach out to us at info@secretometx.com. You can find further contact details on the Contact Information section of our website.
Please check back periodically for updates on EAP clinical trials.